DOAC dosing in older patients with nonvalvular atrial fibrillationAn oral anticoagulant is recommended for most patients aged ≥ 65 years with nonvalvular atrial fibrillation (NVAF), to reduce the risk of stroke. Aspirin may benefit people with elevated lipoprotein-a (Lp(a)) Recognized as an independent risk factor for cardiovascular disease, there are no approved therapies. Alberta pharmacists develop DOAC drug interactions management resource Practice a tool compares drug interactions with the four marketed DOACs, focusing on interactions commonly encountered in thrombosis/cardiology-based practices New Canadian guideline for using GLP-1 agonists and SGLT2 inhibitors for cardiorenal risk reduction GLP-1 receptor agonists and SGLT2 inhibitors have proven cardiorenal benefits in patients with and without type 2 diabetes. QUIZ: Vascular anomalies in childhood Do you know when and how to treat hemangiomas, and when to refer? Update to Canadian guidelines on managing pediatric dyslipidemia Provide an approach to the detection, evaluation and management of dyslipidemia in children and adolescents. Bad mix: hot summer days and anti-platelet medications, beta-blockers The meds plus heat associated with an increased risk for myocardial infraction. Pollution is linked to deadly heart arrhythmias Study indicates that people at high risk of ventricular arrhythmias should check daily pollution levels. QUIZ: Test your knowledge of detecting and managing dyslipidemia in children Should all children be screened for dyslipidemia? How much do you know about the detection and management of dyslipidemia in children and youth? Risk of myopericarditis with Pfizer COVID-19 vaccine in children 5 to 11 years Danish study examines risk of myopericarditis after COVID-19 vaccination in children, compared with adolescents and background incidence. First Previous 24 25 26 27 28 Next Last
